You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 246 No. 9, August 28, 1981 TABLE OF CONTENTS
  JAMA
  •  Online Features
  COMMENTARY
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Coffee and Pancreatic Cancer

The Problems of Etiologic Science and Epidemiologic Case-Control Research

Alvan R. Feinstein, MD; Ralph I. Horwitz, MD; Walter O. Spitzer, MD; Renaldo N. Battista, MD

JAMA. 1981;246(9):957-961.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE RECENT report that coffee may cause pancreatic cancer1 was presented in a pattern that has become distressingly familiar. The alleged carcinogen is a commonly used product. The report was given widespread publicity before the supporting evidence was available for appraisal by the scientific community, and the public received renewed fear and uncertainty about the cancerous hazards lurking in everyday life.

The research on coffee and pancreatic cancer was done with the case-control technique that has regularly been used in epidemiologic circumstances where the more scientifically desirable forms2 of clinical investigation—a randomized controlled trial or a suitably performed observational cohort study—are either impossible or unfeasible. In case-control studies, the investigators begin at the end, rather than at the beginning, of the cause-effect pathway. The cases are selected from persons in whom the target disease has already developed. The controls are selected from persons in whom that disease has not . . . [Full Text PDF of this Article]


Author Affiliations

From the Robert Wood Johnson Clinical Scholars Program, Yale University School of Medicine, New Haven, Conn (Drs Feinstein and Horwitz), and the Cooperative Studies Program Support Center, Veterans Administration Hospital, West Haven, Conn (Dr Feinstein), and the McGill Cancer Center, McGill University (Dr Spitzer), and the Kellogg Center for Advanced Studies in Primary Care, Montreal General Hospital (Drs Spitzer and Battista), Montreal.


Footnotes

Reprint requests to Robert Wood Johnson Clinical Scholar Program, Yale University School of Medicine, 333 Cedar St, Box 3333, New Haven, CT 06510 (Dr Feinstein).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1981 American Medical Association. All Rights Reserved.